David G. Bostwick, MD, MBA, FCAP, presented “Intratumoral Immunotherapy for Cancer: Update 2024 of a Novel Approach” during the 27th Annual Southwest Prostate Cancer Symposium conference on October 17, 2024, in Scottsdale, Arizona.
How to cite: Bostwick, David G. “Intratumoral Immunotherapy for Cancer: Update 2024 of a Novel Approach.” October 17, 2024. Accessed Feb 2025. https://grandroundsinurology.com/intratumoral-immunotherapy-for-cancer-update-2024-of-a-novel-approach/
Intratumoral Immunotherapy for Cancer: Update 2024 of a Novel Approach – Summary
David G. Bostwick, MD, MBA, FCAP, discusses the potential of intratumoral immunotherapy in treating prostate cancer and other challenging malignancies. In this 19-minute presentation, Dr. Bostwick reflects on the historical limitations of immunotherapy in prostate cancer. He shares a pioneering approach combining focal cryoablation with multiple immunotherapies, including PD-1 inhibitors, CTLA-4 blockade, and GM-CSF, to effectively unmask and expose tumor antigens.
Dr. Bostwick presents a remarkable case of a metastatic prostate cancer patient who achieved complete remission lasting over nine years after a single outpatient treatment session. Retrospective studies and ongoing phase II trials suggest a 31% abscopal effect and significant disease control, indicating the approach’s potential across different cancers. Preliminary results in prostate, bladder, cervical, and pancreatic cancers show encouraging responses with minimal adverse effects.
About the 27th Annual Southwest Prostate Cancer Symposium:
Presented by Program Chairs Nelson N. Stone, MD, Richard G. Stock, MD, and William K. Oh, MD, this conference educated attendees about advances in the management of localized and advanced prostate cancer, with a focus on imaging, technology, and training in the related devices. It included a scientific session, as well as live demonstrations of surgical techniques. You can learn more about the conference here.
ABOUT THE AUTHOR
Dr. David G. Bostwick, MD, MBA,FCAP,is the founder and Chief Executive Officer of Bostwick Laboratories (a division of Poplar Healthcare), Chief Medical Officer of Granger Genetics, and Chief Medical Officer of Rampart Health. He trained at the University of Maryland and Stanford University, and was formerly a Professor of Urology and Pathology at the Mayo Clinic from 1991 to 1999. Dr. Bostwick is internationally renowned, with 40 years of experience and interest in prostate cancer, bladder cancer and urologic diseases. He has previously held appointments at the National Cancer Institute, Stanford University, University of Chicago, University of Maryland, and Mayo Clinic.
Dr. Bostwick has authored 17 books, more than 25 book chapters, and more than 475 professional papers. Dr. Bostwick has presented more than 2000 lectures around the world, and has served as Principal Investigator or Co-Investigator for more than 10 clinical trials.
